Zydus Lifesciences receives approval for methylene blue injection  

Madhu Balaji Updated - December 06, 2023 at 02:56 PM.

Zydus Lifesciences has received final assent from the USFDA to manufacture and market methylene blue Injection. The company’s methylene blue injection — 10mg/2ml and 50mg/5ml — is the generic version of the reference listed drug (RLD) ProvayBlue Injection.

Zydus said in its regulatory filing that the injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. The company also observed that it had an annual sale of approximately $73.4 million in the US. 

The company’s stock inched up by 0.61 per cent on the NSE, trading at ₹637.90 at 2:25 pm.

Sign up for newsletters, unlock features and do more on The Hindu
LOG IN
Support our reporting.
SUBSCRIBE NOW
Published on December 6, 2023 09:26
Tags

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
or read this article by Downloading TheHindu Businessline News app
If you're already a subscriber
Access just this article

TheHindu Businessline operates by its editorial values to provide you quality journalism.

Support our reporting.
Subscribe
This is your last free article.
to read unlimited content from TheHindu Businessline
Subscribe
Stay updated on Markets,Economy, Agri & more.
Get TheHindu Businessline News App on
Recommended Articles